β-lactams continue to play a central role in pneumonia management, but their effectiveness increasingly depends on appropriate patient selection, optimized dosing, and antimicrobial stewardship. While new agents have expanded therapeutic options against multidrug-resistant pathogens, none provide universal coverage. Future progress will rely on improved diagnostics, a deeper understanding of resistance evolution, and the integration of innovative therapeutic strategies to preserve the clinical utility of β-lactams.
Esposito et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: